Total Payments
$234,888
2024 Payments
$51,229
Companies
12
Transactions
180
Medicare Patients
1,870
Medicare Billing
$357,948
Payment Breakdown by Category
Consulting$176,070 (75.0%)
Other$25,237 (10.7%)
Travel$22,195 (9.4%)
Research$7,920 (3.4%)
Food & Beverage$3,425 (1.5%)
Education$39.60 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $176,070 | 56 | 75.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25,237 | 14 | 10.7% |
| Travel and Lodging | $22,195 | 46 | 9.4% |
| Unspecified | $7,920 | 9 | 3.4% |
| Food and Beverage | $3,425 | 52 | 1.5% |
| Education | $39.60 | 3 | 0.0% |
Payments by Type
General
$226,967
171 transactions
Research
$7,920
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $61,354 | 50 | $0 (2024) |
| Merck Sharp & Dohme LLC | $55,350 | 40 | $0 (2024) |
| AstraZeneca UK Limited | $41,248 | 13 | $0 (2023) |
| F. Hoffmann-La Roche AG | $20,133 | 20 | $0 (2024) |
| Genentech USA, Inc. | $16,580 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $12,642 | 19 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $7,075 | 8 | $0 (2024) |
| Roche Diagnostics Corporation | $7,059 | 4 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $6,244 | 6 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,440 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,229 | 28 | Merck Sharp & Dohme LLC ($24,444) |
| 2023 | $31,379 | 24 | AstraZeneca UK Limited ($11,390) |
| 2022 | $14,756 | 5 | AstraZeneca UK Limited ($8,220) |
| 2021 | $26,844 | 17 | AstraZeneca Pharmaceuticals LP ($6,165) |
| 2020 | $31,878 | 13 | AstraZeneca UK Limited ($13,358) |
| 2019 | $23,927 | 25 | AstraZeneca Pharmaceuticals LP ($13,913) |
| 2018 | $20,054 | 23 | AstraZeneca Pharmaceuticals LP ($11,809) |
| 2017 | $34,820 | 45 | AstraZeneca Pharmaceuticals LP ($11,324) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Roche Diagnostics Corporation | — | Travel and Lodging | Cash or cash equivalent | $677.32 | General |
| Category: None | ||||||
| 11/27/2024 | Roche Diagnostics Corporation | — | Travel and Lodging | Cash or cash equivalent | $677.32 | General |
| Category: None | ||||||
| 11/14/2024 | Roche Diagnostics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,590.00 | General |
| Category: None | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $7,320.00 | General |
| 11/13/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/05/2024 | Roche Diagnostics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,114.00 | General |
| Category: None | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Consulting Fee | Cash or cash equivalent | $3,670.00 | General |
| Category: BioOncology | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Travel and Lodging | Cash or cash equivalent | $309.00 | General |
| Category: BioOncology | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $82.97 | General |
| Category: BioOncology | ||||||
| 10/31/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $20.30 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $11,308.80 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $201.72 | General |
| 10/30/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $128.19 | General |
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 10/03/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $365.91 | Research |
| Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology | ||||||
| 09/09/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 08/25/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,440.00 | General |
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $6,165.00 | General |
| Category: Oncology | ||||||
| 06/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $715.76 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 06/28/2024 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| 06/28/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $109.00 | General |
| 06/01/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $82.65 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Neoadjuvant targeted therapy in resectable non-small cell lung cancer:nsclc current and future perspectives | F. Hoffmann-La Roche AG | $3,191 | 1 |
| LCMC3 | F. Hoffmann-La Roche AG | $1,763 | 3 |
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $1,316 | 2 |
| Phase II Study of TKIs as Neoadjuvant Therapy in Stage I-III Resectable NSCLC with ALK, ROS1, NTRK, or BRAFV600 Alterations | F. Hoffmann-La Roche AG | $1,141 | 1 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
| PHASE II STUDY OF TKIS AS NEOADJUVANT THERAPY IN STAGE II III RESECTABLE NSCLC WITH ALK, ROS1, NTRK OR BRAF V600 ALTERATIONS | F. Hoffmann-La Roche AG | $143.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 619 | 1,192 | $713,575 | $112,341 |
| 2022 | 4 | 362 | 705 | $445,220 | $73,177 |
| 2021 | 6 | 437 | 1,052 | $632,075 | $105,900 |
| 2020 | 10 | 452 | 872 | $455,420 | $66,530 |
Total Patients
1,870
Total Services
3,821
Medicare Billing
$357,948
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 190 | 389 | $283,970 | $47,007 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 222 | 446 | $243,070 | $36,120 | 14.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 105 | 214 | $80,250 | $12,015 | 15.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 73 | 73 | $76,285 | $11,173 | 14.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 12 | 30 | $15,600 | $3,194 | 20.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 40 | $14,400 | $2,832 | 19.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 133 | 275 | $203,500 | $35,467 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 132 | 296 | $161,320 | $25,239 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 45 | 45 | $47,025 | $7,166 | 15.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 52 | 89 | $33,375 | $5,306 | 15.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 139 | 335 | $241,200 | $42,933 | 17.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 151 | 446 | $243,070 | $37,849 | 15.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 32 | 105 | $53,025 | $9,990 | 18.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 49 | 49 | $51,205 | $8,097 | 15.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 51 | 102 | $38,250 | $6,030 | 15.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 15 | 15 | $5,325 | $1,003 | 18.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 145 | 366 | $190,320 | $25,324 | 13.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 92 | 175 | $120,750 | $17,291 | 14.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 71 | 137 | $48,635 | $6,360 | 13.1% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 40 | 40 | $39,790 | $6,045 | 15.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 20 | 53 | $26,235 | $5,066 | 19.3% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 30 | 41 | $6,365 | $1,934 | 30.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 15 | 15 | $12,000 | $1,807 | 15.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 15 | 19 | $4,525 | $1,382 | 30.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 12 | $4,140 | $811.50 | 19.6% |
About Dr. Jamie Chaft, MD
Dr. Jamie Chaft, MD is a Internal Medicine healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1861659500.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jamie Chaft, MD has received a total of $234,888 in payments from pharmaceutical and medical device companies, with $51,229 received in 2024. These payments were reported across 180 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($176,070).
As a Medicare-enrolled provider, Chaft has provided services to 1,870 Medicare beneficiaries, totaling 3,821 services with total Medicare billing of $357,948. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location New York, NY
- Active Since 05/20/2008
- Last Updated 04/06/2015
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1861659500
Products in Payments
- TAGRISSO (Drug) $47,003
- TECENTRIQ (Biological) $13,529
- Alecensa (Biological) $12,370
- KEYTRUDA (Biological) $7,188
- LIBTAYO (Biological) $7,075
- IMFINZI (Drug) $6,850
- Avastin (Biological) $3,947
- IMFINZI (Biological) $3,475
- TABRECTA (Drug) $2,500
- RYBREVANT (Drug) $2,204
- Tecentriq (Biological) $2,128
- OPDIVO (Biological) $1,130
- Non-Covered Product (Drug) $116.32
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in New York
Dr. Stephen Saletan, M.d, M.D
Internal Medicine — Payments: $2.7M
Internal Medicine $2.7M
Michael Schuster, Md, MD
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Dr. Ziad Ali, Md Dphil, MD DPHIL
Internal Medicine — Payments: $1.7M
Internal Medicine $1.7M
Dr. James Underberg, Md, MD
Internal Medicine — Payments: $1.5M
Internal Medicine $1.5M
Dr. Ricky Hsu, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Gail Roboz, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M